Product details:
| ISBN13: | 9780323898218 |
| ISBN10: | 0323898211 |
| Binding: | Hardback |
| No. of pages: | 900 pages |
| Size: | 234x190 mm |
| Weight: | 450 g |
| Language: | English |
| 700 |
Category:
Adenoviral Vectors for Gene Therapy
Edition number: 3
Publisher: Academic Press
Date of Publication: 1 April 2025
Normal price:
Publisher's listprice:
EUR 231.00
EUR 231.00
Your price:
90 374 (86 071 HUF + 5% VAT )
discount is: 10% (approx 10 042 HUF off)
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
Click here to subscribe.
Availability:
Not yet published.
Long description:
Adenoviral Vectors for Gene Therapy, Third Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research.
The fully updated and expanded third edition covers the basic biology of adenoviruses, highlights the potential use adenoviral vectors for the treatment of disease including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for vet applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine application and virotherapy, and oncolytic adenoviruses for anti-tumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
The fully updated and expanded third edition covers the basic biology of adenoviruses, highlights the potential use adenoviral vectors for the treatment of disease including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for vet applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine application and virotherapy, and oncolytic adenoviruses for anti-tumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
Table of Contents:
1. Adenovirus Structure
2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms
3. Adenovirus Replication
4. Adenoviral Vector Construction I: Mammalian Systems
5. Adenoviral Vector Construction II: Bacterial Systems
6. Upstream Bioprocess for Adenovirus Vectors
7. Propagation of Adenoviral Vectors: Use of PER.C6T Cells
8. Purification of Adenovirus
9. Targeted Adenoviral Vectors I: Transductional Targeting
10. Targeted Adenoviral Vectors III: Transcriptional Targeting
11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration
12. Molecular Design of Oncolytic Adenoviruses
13. Conditionally Replicative Adenoviruses-Clinical Trials
14. Innate Immune Response to Adenovirus Vector Administration In Vivo
15. Antibodies against Adenoviruses
16. Methods to Mitigate Immune Responses to Adenoviral Vectors
17. Helper-Dependent Adenoviral Vectors
18. Hybrid Adenoviral Vectors
19. Xenogenic Adenoviral Vectors
20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics
21. Adenoviral Vector Vaccines Antigen Transgene
22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen
23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer
24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer
25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease
26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease)
27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases
28. Animal Models of Gene Therapy for Cardiovascular Disease
29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy
30. Adenoviral Vectors for RNAi Delivery
31. Imaging and Adenoviral Gene Therapy
32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms
3. Adenovirus Replication
4. Adenoviral Vector Construction I: Mammalian Systems
5. Adenoviral Vector Construction II: Bacterial Systems
6. Upstream Bioprocess for Adenovirus Vectors
7. Propagation of Adenoviral Vectors: Use of PER.C6T Cells
8. Purification of Adenovirus
9. Targeted Adenoviral Vectors I: Transductional Targeting
10. Targeted Adenoviral Vectors III: Transcriptional Targeting
11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration
12. Molecular Design of Oncolytic Adenoviruses
13. Conditionally Replicative Adenoviruses-Clinical Trials
14. Innate Immune Response to Adenovirus Vector Administration In Vivo
15. Antibodies against Adenoviruses
16. Methods to Mitigate Immune Responses to Adenoviral Vectors
17. Helper-Dependent Adenoviral Vectors
18. Hybrid Adenoviral Vectors
19. Xenogenic Adenoviral Vectors
20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics
21. Adenoviral Vector Vaccines Antigen Transgene
22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen
23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer
24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer
25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease
26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease)
27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases
28. Animal Models of Gene Therapy for Cardiovascular Disease
29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy
30. Adenoviral Vectors for RNAi Delivery
31. Imaging and Adenoviral Gene Therapy
32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
